Millennium: The Takeda Oncology Company Release: Subcutaneous Administration of Single-Agent VELCADE Demonstrates Efficacy Consistent with Intravenous Administration

ORLANDO, Fla.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADEĀ® (bortezomib) in patients with relapsed multiple myeloma (MM). These data were presented at the 52nd annual meeting of the American Society of Hematology (ASH), held December 4-7 in Orlando, Florida.

Back to news